United Cannabis (CNABQ) 10-K 28 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 28, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	United Cannabis Corp
Entity Central Index Key	0001436161
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Public Float			$ 24,262,000
Entity Common Stock, Shares Outstanding		77,476,980
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 664,570	$ 825,645
Accounts receivable, net	171,747
Due from related parties	86,971
Inventory	2,552,118	43,200
Other current assets	34,932	23,028
Total current assets	3,510,338	891,873
Construction in process - extraction facilities	1,937,187	832,697
Cultivation facility and laboratory equipment and office furniture and fixtures, net of accumulated amortization and depreciation of $433,148 and $39,385 at December 31, 2018 and 2017, respectively	2,119,745	199,821
Granted patents, net of accumulated amortization of $9,795 and $2,679 for December 31, 2018 and 2017, respectively	132,522	139,638
Intangible assets	270,508	170,519
Other Assets	84,329
Goodwill	4,838,603	4,838,603
Total assets	12,893,232	7,073,151
Current liabilities:
Accounts payable	1,163,398	371,711
Accrued expenses	139,103	10,184
Construction contracts payable	888,686
Installment loans payable	57,799	46,667
Current portion of deferred revenue	23,750	180,000
Accrued wages payable to officers and directors		310,401
Notes payable for advances from and prior wages payable to officers and directors	1,155,436	261,348
Notes payable, net of a $62,917 debt discount	1,512,083
Arbitration reserve	650,000
Total current liabilities	5,590,255	1,180,311
Long term liabilities:
Deferred revenue, net of current portion		23,750
Total liabilities	5,590,255	1,204,061
COMMITMENTS AND CONTINGENCIES - Note 21
STOCKHOLDERS' EQUITY
Preferred stock, 10,000,000 shares authorized; 2,000 Series A shares outstanding at December 31, 2018 and December 31, 2017, respectively	2,200	2,200
Common stock, 100,000,000 shares authorized; 77,467,980 and 62,862,066 outstanding at December 31, 2018 and December 31, 2017, respectively	46,939,646	21,186,888
Accumulated deficit	(39,374,396)	(15,269,845)
Total equity attributable to stockholders of the Company	7,567,450	5,919,243
Non-controlling interest (deficit)	(264,473)	(50,153)
Total stockholders' equity	7,302,977	5,869,090
Total liabilities and stockholders' equity	$ 12,893,232	$ 7,073,151

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Net of accumulated depreciation on facility	$ 433,148	$ 39,385
Accumulated amortization on granted patents	9,795	2,679
Notes payable, debt discount	$ 62,917	$ 62,917
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	77,467,980	62,862,066
Preferred Class A [Member]
Preferred stock, shares outstanding	2,000	2,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Product revenues	$ 6,867,593
Licensing fees	180,000	180,000
Revenues, affiliate	197,032	182,323
Total revenues	7,244,625	362,323
Cost of revenues:
Cost of revenues	5,840,613	134,795
Gross profit	1,404,012	227,528
Operating expenses:
Marketing, advertising and new business development	277,705	142,094
Research and development	1,040,265	293,968
Legal, accounting, consulting and public reporting	1,595,740	878,257
General and administrative	4,850,738	1,440,208
Share-based expense for stock options granted to officers, directors and employees	14,890,347	2,661,159
Total operating expenses	22,654,795	5,415,686
Loss from operations	(21,250,783)	(5,188,158)
Other income (expense):
Interest expense	(195,082)	(61,534)
Amortization of debt discount	(55,833)
Loss on extinguishment of debt and repurchase of warrants		(248,892)
Loss on settlement of dispute		(122,139)
Loss on conversion of note	(825,067)
Loss on issuance of common stock	(1,992,105)	(582,881)
Loss before taxes on income	(24,318,870)	(6,203,604)
Provision for taxes on income
Net Loss	(24,318,870)	(6,203,604)
Loss attributable to non-controlling interests	214,319	296,092
Net Loss attributable to common shareholders	$ (24,104,551)	$ (5,907,512)
Basic and diluted net loss per share:	$ (0.35)	$ (0.11)
Basic and diluted weighted-average common shares outstanding:	69,060,355	54,261,197

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Beginning balance at Dec. 31, 2016		$ 8,885,674	$ (9,362,333)		$ (476,659)
Beginning balance, shares at Dec. 31, 2016		50,650,994
Issuance of preferred stock	$ 2,200				2,200
Issuance of preferred stock, shares	2,000
Consolidation of Cannabinoid Research Development Limited as a 50% variable interest entity				(18,872)	(18,872)
Consolidation of Cannabinoid Research Development Limited as a 50% variable interest entity, shares
Shares issued for payables and accrued expenses		$ 93,002			93,002
Shares issued for payables and accrued expenses, shares		66,000
Conversion of notes payable		$ 381,576			381,576
Conversion of notes payable, shares		379,100
Shares issued for advisory board services		$ 113,336			113,336
Shares issued for advisory board services, shares		111,173
Shares issued for professional services		$ 249,833			249,833
Shares issued for professional services, shares		239,700
Options and warrants issued to officers and directors		$ 2,660,159			2,660,159
Warrants issued for advisory board services					249,835
Shares issued as compensation		$ 170,233			170,233
Shares issued as compensation, shares		163,534
Shares issued in settlement of disputes		$ 102,139			102,139
Shares issued in settlement of disputes, shares		100,000
Sale of common stock		$ 208,982			208,982
Sale of common stock, shares		271,136
Shares issued - draws under our equity line of credit		$ 3,228,954			3,228,954
Shares issued - draws under our equity line of credit, shares		3,714,238
Shares issued to acquire Prana Therapeutics, Inc.		$ 4,870,500		264,811	5,135,311
Shares issued to acquire Prana Therapeutics, Inc., shares		5,730,000
Exercise of options and warrants		$ 222,500			222,500
Exercise of options and warrants, shares		1,436,191
Net loss			(5,907,512)		(5,907,512)
Non-Controlling Interests - Cannabinoid Research & Development Limited				(291,918)	(291,918)
Non-Controlling Interests - Cannabinoid Research & Development Limited, shares
Non-Controlling Interest - Prana Therapeutics, Inc.				(4,174)	(4,174)
Non-Controlling Interest - Prana Therapeutics, Inc., shares
Ending balance at Dec. 31, 2017	$ 2,200	$ 21,186,888	(15,269,845)	(50,153)	5,869,090
Ending balance, shares at Dec. 31, 2017	2,000	62,862,066
Conversion of notes payable		$ 1,828,741			1,828,741
Conversion of notes payable, shares		3,077,801
Shares issued for advisory board services		$ 96,000			96,000
Shares issued for advisory board services, shares		147,227
Shares issued for professional services		$ 335,852			335,852
Shares issued for professional services, shares		611,497
Options and warrants issued to officers and directors		$ 14,890,347			14,890,347
Warrants issued for advisory board services		102,640			102,640
Shares issued as compensation		$ 297,400			297,400
Shares issued as compensation, shares		363,163
Sale of common stock		$ 152,797			152,797
Sale of common stock, shares		192,799
Shares issued - draws under our equity line of credit		$ 8,048,981			8,048,981
Shares issued - draws under our equity line of credit, shares		10,212,426
Net loss			(24,104,551)		(24,104,551)
Non-Controlling Interests - Cannabinoid Research & Development Limited				(181,689)	(181,689)
Non-Controlling Interests - Cannabinoid Research & Development Limited, shares
Non-Controlling Interest - Prana Therapeutics, Inc.				(32,631)	(32,631)
Non-Controlling Interest - Prana Therapeutics, Inc., shares
Ending balance at Dec. 31, 2018	$ 2,200	$ 46,939,646	$ (39,374,396)	$ (264,473)	$ 7,302,977
Ending balance, shares at Dec. 31, 2018	2,000	77,466,979

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (24,318,870)	$ (6,203,604)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt discount	55,833	30,453
Non-cash interest expense	104,010	61,534
Depreciation and amortization	400,907	40,161
Share-based compensation, net	15,722,239	3,286,565
Discount on issuance of shares of common stock	1,992,104	582,881
Loss on settlement of dispute		122,139
Loss on conversion of convertible notes	825,067
Loss on extinguishment of debt and repurchase of warrants		248,892
Changes in operating assets and liabilities:
Inventory	(2,508,918)	(43,200)
Accounts receivable	(171,747)	24,484
Other current assets	(11,904)	(23,028)
Due from related party	(86,971)	(26,775)
Accounts payable and accrued expenses	931,521	(89,860)
Deferred revenue	(180,000)	(180,000)
Accrued wages payable to officers and directors		213,698
Notes payable to and advances from officers and directors		77,384
Net cash used in operating activities	(7,246,729)	(1,878,276)
Investing activities:
Cash acquired upon acquisition of subsidiary		363,134
Improvements to cultivation and extraction facilities and purchase of equipment	(2,529,520)	(621,731)
Purchase of intangible assets	(99,989)	(197,164)
Deposits and return of deposit	(84,329)	(32,500)
Cash portion of settlement of dispute		(20,000)
Net cash provided by (used in) investing activities	(2,713,838)	(508,261)
Financing activities:
Proceeds from issuance of common stock - equity financing line	6,091,090	2,682,750
Net proceeds from issuance of notes payable	1,500,000
Net proceeds from issuance of convertible debt	845,000
Proceeds from proposed joint venture that was never formed - arbitration reserve	650,000
Proceeds from advances from officers and directors	583,687	254,942
Repayment of convertible debt and notes payable		(31,000)
Proceeds from issuance of common shares and exercise of warrants	118,583	192,869
Proceeds from installment note	76,715
Payments on installment loans	(65,583)
Net cash provided by (used in) financing activities	9,799,492	3,099,561
Net increase (decrease) in cash	(161,075)	713,024
Cash, beginning of period	825,645	112,621
Cash, end of period	664,570	825,645
Supplemental schedule of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Common shares issued in the acquisition of Prana Therapeutics, Inc.		4,870,500
Common stock issued upon exercise of cashless warrants		350,000
Reduction of convertible notes payable due to the conversion by Tangiers Global	888,750
Issuance of common stock upon conversion of debt and loss on extinguishment of debt		381,576
Conversion to notes payable for advances from officers and directors	310,401
Acquisition of equipment from related party		$ 99,200

BUSINESS ORGANIZATION AND NATUR

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS United Cannabis Corporation ("we", "our", "us", "UCANN", or “the Company”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the prior President of the Company. In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry. On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock. In connection with this transaction: · Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry. · The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement. · Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014. · Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President. · A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014. UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation. On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we entered into a new business and no longer had any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. On July 14, 2017, we completed the acquisition of Prana Therapeutics, Inc. (“Prana”) in a one-for-one exchange of 5,730,000 shares of common stock of the Company for 5,730,000 of common stock of Prana. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share on the OTC QB exchange on July 14, 2017, including the cost to purchase 400,000 shares of Prana common stock for $200,000. Prana is a polymolecular botanical drug development company focused on developing targeted therapeutics for prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer. Management elected to purchase Prana, because of the successful indication of the effectiveness of their Epidiferphane™ chemical formulation in the treatment of (i) the negative side effects of chemotherapy, (ii) inflammation and pain associated with arthritis and back-centric pain, and (iii) the potential shrinkage of brain tumors. Recently, we elected to focus a significant portion of our assets, human resources and financial capital on the manufacturing and selling of a variety of cannabidiol centric products derived from industrial hemp plants. We constructed a state-of-the-art extraction facility; and, hired and trained specialized extraction personnel and laboratory technicians that enable us to convert components of industrial hemp flower to finished CBD products. In order to help provide a consistent supply of industrial hemp flower for our extraction facility, we purchased farming equipment and leased hundreds of acres of farm land on which we are growing a crop of industrial hemp. It is our intent to grow at least one crop of industrial hemp plants per calendar year and to harvest a sufficient amount of industrial hemp flower from our crop to supply our extraction facility on a vertically integrated basis. As of December 31, 2018, we have expended approximately $2,800,000 on facilities, farm equipment and crop planting and cultivation, as a result of electing to vertically integrate the hemp centric portion of our business Government Regulation

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation At March 31, 2017, we concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017. PTI was purchased on July 14, 2017, and its assets and liabilities are included in the consolidated balance sheets at December 31, 2018 and 2017, and their results of operations are included in the consolidated financial statements for the years ended December 31, 2018 and 2017. Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at December 31, 2018, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the years ended December 31, 2018 and 2017. Cash and Cash Equivalents Accounts Receivable, Net Inventory – Property, Plant and Equipment, net Granted Patents, Net – Intangible Assets – Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of December 31, 2018 or December 31, 2017. Goodwill fl – Purchase Price Allocation – “ Business Combinations ” Fair Value Measurements and Disclosures Deferred Revenue Revenue Recognition Revenue from Contracts with Customers Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Revenue from Contracts with Customers. We have licensed Prana Hemp Prana Hemp Prana Hemp Prana Hemp Prana Hemp Revenue from Contracts with Customers. Cost of Revenues Research and Development Expenses General and Administrative Expenses Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the years ended December 31, 2018 or 2017, respectively. Commitments and Contingencies – Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Years Ended December 31, 2018 2017 Warrants to purchase common stock 1,309,033 1,209,025 Stock options 26,837,300 6,637,500 28,146,333 7,846,525 Other Comprehensive Income (Loss) Concentration of Credit Risk Recently Issued Accounting Pronouncements In June 2018, the FASB issued updated ASU 2018-07 – Compensation – Stock Compensation (Topic 718) Reclassification

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2018
GOING CONCERN [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the year ended December 31, 2018, we incurred losses of $24,318,870, used cash of $7,246,729 in our operating activities, had a working capital deficit of $2,079,917 and had an accumulated deficit of $39,374,396 at December 31, 2018. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

DUE FROM RELATED PARTY

DUE FROM RELATED PARTY	12 Months Ended
	Dec. 31, 2018
Due From Related Party
DUE FROM RELATED PARTY	NOTE 4 – DUE FROM RELATED PARTY Under the terms of licensing agreements, we completed sales to related parties, Advesa, Inc. and NutriMed, LLC, in the aggregate amount of $197,032 and $182,323 for the years ended December 31, 2018 and December 31, 2017, respectively. Amounts due from related from related parties include the following: December 31, 2018 2017 Advesa, Inc. $ 42,349 $ — NutriMed, LLC 44,622 — $ 86,971 $ — In the normal course of business, we make non-interest-bearing advances to Advesa, Inc. (“Advesa’), which is controlled by one of our officers and directors, and we receive licensing fees from the sale of products licensed to Advesa by the Company. In the normal course of business, we sell products to NutriMed, LLC, which is controlled by two of our officers and directors. The products that we sell to NutriMed, LLC are at a price equivalent to the whole sale price that we charge to unrelated, third party distributors.

OPERATING LEASES

OPERATING LEASES	12 Months Ended
	Dec. 31, 2018
Leases [Abstract]
OPERATING LEASES	NOTE 5 – OPERATING LEASES Administrative Offices and Hemp Laboratory – Golden, Colorado Effective August 1, 2017, we entered into a triple net lease of approximately 9,882 square feet of commercial space in Golden, Colorado in which our administrative offices and hemp laboratory are located. The term of the lease expires on July 31, 2020 and has no option for renewal. Basic rent is $3,302, $3,500 and $3,800 per month through, July 31, 2018, 2019 and 2020, respectively, plus we are responsible for all utilities. It is our intent presently, to renew the lease annual throughout the term of the lease. Extraction and Cultivation Facility – Fort Morgan, Colorado Effective October 1, 2017, we entered into a triple net lease of approximately 40,000 square feet of industrial space located on five (5) acres of land in Weldona, Colorado that we us as our hemp extraction facility and hemp cultivation center. The term of the lease expires on September 31, 2018, with an annual option to renew the lease on an annual basis, that expires on September 30, 2022. The rent is $7,500 per month throughout the term of the lease, plus we are responsible for all utilities. Extraction Facility – Mead, Colorado Effective August 15, 2018, we entered into a triple net lease of approximately 14,300 square feet of industrial space in located in Mead, Colorado that, upon completion tenant modification and installation of extraction equipment, we will use the facility as our main extraction facility in Colorado. The initial term of the lease expires on August 31, 2019, with an annual option to renew the lease for an additional three-year period, on an annual basis. We have made $75,000 security deposit with the landlord in connection with the lease. The monthly lease amount for the initial lease period is $12,596 per month and will increase annually by 3.0% or accordance with a consumer price index calculation, whichever is greater. Testing Lab – Golden, Colorado Effective November 1, 2018, we entered into a triple net lease of approximately 2,100 square feet of commercial space located in Golden, Colorado that we use as our testing laboratory. The term of the lease expires on October 31, 2020, with an option to renew for an additional two-year term exercisable prior to 90 days before the end of the initial term. The basic rent is $2,161 and $2,226 per month through October 31, 2019 and 2020, respectively, plus we are responsible for all utilities. Extraction and Cultivation Facility - Jamaica Our fifty percent (50%) owned subsidiary Cannabinoid Research Development Company Limited (“CRD”) leases approximately 28 acres of land upon which their cultivation and extraction facility is located near Kingston, Jamaica. The land is leased for $1 per year from the father of one of the directors and members of CRD. Future minimum payments for these leases are: For the twelve Months Ending December 31, 2019 2020 2021 2022 2023 $322,101 $304,332 $251,961 $234,321 $113,417

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2018
Inventory Abstract
INVENTORY	NOTE 6 - INVENTORY At December 31, 2018 and 2017, our inventory was, as follows: December 31, 2018 2017 Raw materials $ 1,813,880 $ 15,000 Work-in-process 666,845 — Finished goods 71,393 28,200 $ 2,552,118 $ 43,200

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment, Net [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 7 – PROPERTY, PLANT AND EQUIPMENT, NET December 31, 2018 2017 Cost of construction in process - extraction facility Weldona, Colorado extraction facility: Equipment and leasehold improvements $ — $ 647,947 Mead, Colorado extraction facility Equipment and leasehold improvements 1,743,223 — Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 75,000 Leasehold improvements - cultivation 118,964 109,750 $ 1,937,187 $ 832,697 December 31, 2018 2017 Extraction facility, laboratory equipment, and office furniture and fixtures Weldona extraction facility Equipment and machinery $ 1,269,734 $ — Furniture and fixtures 64,955 — Leasehold improvements 237,581 — Transportation equipment 60,228 — Farm Equipment 531,245 — Golden, Colorado administrative offices: Furniture and fixtures 49,282 21,668 Leasehold improvements — 2,000 Transportation equipment 200,704 81,667 Golden, Colorado industrial hemp laboratory - equipment 39,944 34,651 Remote laboratory equipment 99,220 99,220 2,552,893 239,206 Accumulated amortization and depreciation (433,148 ) (39,385 ) $ 2,119,745 $ 199,821 The amount of depreciation and amortization expense for the year ended December 31, 2018 and 2017 is $393,763

PURCHASE OF PRANA THERAPUETICS,

PURCHASE OF PRANA THERAPUETICS, INC.	12 Months Ended
	Dec. 31, 2018
Purchase Of Prana Therapuetics Inc.
PURCHASE OF PRANA THERAPUETICS, INC.	NOTE 8 – PURCHASE OF PRANA THERAPUETICS, INC. On June 8, 2017, we entered into an agreement to purchase 400,000 shares of Prana Therapeutics, Inc. (“Prana”), in a private offering of their common shares, for a total consideration of $200,000 (“Subscription Agreement’). In accordance with the terms of the Subscription Agreement, we paid Prana $50,000, upon execution of the Subscription Agreement, and committed to remit $50,000 to Prana on September 30, 2017, December 31, 2017 and March 31, 2018, respectively. Subsequently, on July 14, 2017, we completed the acquisition of Prana in a one-for-one exchange of 5,730,000 shares of our common stock for 5,730,000 shares of common stock of Prana. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share of our common stock on the OTC QB exchange on July 14, 2017, including the cost to purchase 400,000 shares of Prana for $200,000. The purchase price for Prana was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. The allocation of the purchase price was, as follows: December 31, Patents $ 52,596 Net assets 522,761 Goodwill 4,495,143 Total $ 5,070,500

GRANTED PATENT

GRANTED PATENT	12 Months Ended
	Dec. 31, 2018
Granted Patent
GRANTED PATENT	NOTE 9 – GRANTED PATENT On August 15, 2017, the United States Patent and Trademark Office issued to the Company US Patent #9730911 (the “Patent”) granting exclusive rights to its proprietary formulations based on compounds extracted from cannabis plant materials; more specifically the composition of matter pertaining to the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter Patent provides protection for our proprietary formulations. The Patent protects the use of suspending both phytocannabinoids and cannabinoids with specific combinations of cannabis derived terpenes in liquid forms with an array of delivery methods including capsule, sublingual, topical, oral, suppository, and vaporization. Cannabinoids referenced in the application include ratios of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabichromenic acid (CBCa), and cannabichromene (CBC). At August 15, 2017, we classified the costs associated with research, legal fees, application costs incurred in the process of being granted the Patent on our consolidated balance sheet in the amount of $142,317, and we began amortizing such cost of the Patent on a straight-line basis over a 15-year period. Amortization expense of the Patent is $7,116 and $2,679 for the year ended December 31, 2018 and 2017, respectively, and accumulated amortization is $9,795 and $2,679 at December 31, 2018 and 2017, respectively.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 10 – INTANGIBLE ASSETS Our intangible assets are comprised of the costs incurred in pursuing provisional patent applications and applications for design mark and trademarks, which have presently not been approved or issued. The costs associated with our intangible assets are amortized on a straight-line basis over estimated useful lives of 15 years for patents and 10 years for design marks and trademarks, once the applications are approved. Costs associated with applications that are not approved will be expensed in the period that the application is rejected or abandoned.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
ACCRUED EXPENSES	NOTE 11 – ACCRUED EXPENSES Our accrued expenses consist of: December 31, 2018 2017 Accrued wages and related expenses $ 126,345 $ 10,184 Accrued interest expense 2,572 — Other accrued expenses 10,186 — Total accrued expenses $ 139,103 $ 10,184

INSTALLMENT LOANS PAYABLE

INSTALLMENT LOANS PAYABLE	12 Months Ended
	Dec. 31, 2018
Installment Loans Payable
INSTALLMENT LOANS PAYABLE	NOTE 12 – INSTALLMENT LOANS PAYABLE Installment loans payable consist of a 48-month installment loan for the purchase of a truck that is used at our extraction facility, as well as a 36-month installment loan for the purchase an SUV used for Company purposes. The outstanding balance on the 48-month installment loan was $0 and $46,667 at December 31, 2018 and 2017, respectively. The terms of the 48-month installment loan specify monthly payments of $955; however, we are making payments of $6,955 per month to pay the loan off in a nine-month period. As a result of our intentions to pay the loan off in nine months, the entire balance of the 48-month installment loan has been classified as a current liability; this installment loan was fully paid at December 31, 2018. The outstanding balance on the 36-month installment loan was $57,799 and $0 at December 31, 2018 and 2017, respectively. The terms of the 36-month installment loan specify monthly payments of $2,160, however, we are making payments of $6,500 per month to pay the loan off within a one-year period. As a result of our intentions to pay off the loan within one year, the entire balance of the 36-month installment loan has been classified as a current liability.

DEFERRED REVENUE

DEFERRED REVENUE	12 Months Ended
	Dec. 31, 2018
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE	NOTE 13 – DEFERRED REVENUE Our deferred revenue consists of: December 31, 2018 2017 Deferred revenue – WeedMD $ 23,750 $ 203,750 Less – current portion (23,750 ) (180,000 ) Deferred revenue, net of current portion $ — $ 23,750 On June 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and we recognized $150,000 of this amount as revenue during the period July 1, 2014 through December 31, 2014, based upon our initial three-year estimate of the service period involved. Based on recent discussions with WMD, we now expect to deliver the remaining consulting services and use of our intellectual property to WMD on a relatively consistent monthly basis during the four-year period January 1, 2015 through December 31, 2018. Accordingly, we are now recognizing $15,000 of deferred revenue per month. We recognized $180,000 of revenue applicable to this arrangement, in each of the years ended December 31, 2018 and 2017.

NOTE PAYABLE

NOTE PAYABLE	12 Months Ended
	Dec. 31, 2018
CONVERTIBLE NOTE PAYABLE [Abstract]
NOTE PAYABLE	NOTE 14 – NOTE PAYABLE During the year ended December 31, 2018, we issued a note to an unaffiliated third party, Tangiers Global, LLC (“Tangiers”), in the amount of $1,575,000 (“Note”), the terms of which allow us to draw down on the Note in tranches, upon our election. The proceeds of the Note were used to purchase equipment and for general working capital purposes. The debt discount on the Note are amortized on a straight-line basis from the issue date, which approximates the effective interest rate method, over the term of the note, and this amortization is included in interest expense in our consolidated statements of operations. The Company may pay the Note at any time prior to the Maturity Date. Until the 60th day after the date of each funding, the Company may pay the principal of the Note, plus a premium of 10%, in addition to outstanding interest, without the Holder’s consent. From the 61st day after the date of each funding to the 120th date after the date of each funding, the Company may pay the principal of the Note, plus a premium of 20%, in addition to outstanding interest, without the Holder’s consent. From the 121st day after the date of each funding to the 180th day after the date of each funding, the Company may pay the principal of the Note, plus a premium of 30%, in addition to outstanding interest, without the Holder’s consent. After the Maturity Date, the Note may only be paid with the Holder’s consent. Tangiers is entitled, at its option, at any time, after the Maturity Date of each funding to convert all or any part of the unpaid principal of the Note into shares of the Company’s common stock at a price per share equal to 70% of the average of the two lowest trading prices of the Company’s common stock during the 15 consecutive trading days ending on the latest complete trading day prior to the conversion date. On February 11, 2019, the Company agreed to borrow up to $1,575,000 from Tangiers. The loan is evidenced by a promissory note which will be funded in a series of tranches, each of which will bear interest at 5% per year. The first tranche was funded on February 13, 2019. The following table summarizes the Note outstanding as of December 31, 2018 and 2017: December 31, Issue Date Security Maturity Date Interest Rate Draws Under the Note 2018 2017 11/05/2018 Unsecured 5/04/2019 5% First Tranche $ 525,000 $ — 12/05/2018 Unsecured 6/3/2019 5% Second Tranche 525,000 — 12/26/2018 Unsecured 6/24/2019 5% Third Tranche 525,000 — Less unamortized discount (62,917 ) — $ 1,512,083 $ — Upon default, the Note is payable in cash in an amount equal to 130% of the principal balance “Mandatory Default Amount,” plus additional interest on the Mandatory Default Amount from the date of issuance at a rate of 12%. The noteholder may elect to convert Mandatory Default Amount into shares of our common stock at a conversion price equal to 70% of the average of the two lowest trading prices during the 15-day consecutive Trading Days prior to the date the noteholder elects to convert. On September 29, 2018, we converted a $600,000 convertible note and recognized a loss of $466,744 on the conversion of such convertible note for the year ended December 31, 2018. On September 29, 2018, we converted a $288,750 convertible note and recognized a loss of $358,323 on the conversion of such convertible note for the year ended December 31, 2018. During the years ended December 31, 2018 and 2017 we recognized $55,833 and $30,453 of amortization of debt discounts, respectively. These amounts are included in interest expense in our consolidated statements of operations. Additionally, we recognized $2,572 and $0.00 of interest expense applicable to the Note during the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, and 2017, $2,572 and $0.00, respectively, of this interest carried as accrued expenses on our consolidated balance sheets.

NOTES PAYABLE TO AND ADVANCES F

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS	12 Months Ended
	Dec. 31, 2018
NOTES PAYABLE, RELATED PARTIES [Abstract]
NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS	NOTE 15 – NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS Notes payable to and advance from officers and directors consisted of the following, at December 31, 2018 and 2017: December 31, 2018 2017 Note payable to Earnie Blackmon, an officer and director $ 840,807 $ 246,459 Note payable to Tony Verzura, an officer and director 160,247 14,889 Note payable to Chad Ruby, an office and director 154,382 — $ 1,155,436 $ 261,348 On April 6, 2016, we borrowed $25,000 from Ernest Blackmon and $25,000 from Tony Verzura and used the proceeds to repay principal and interest applicable on our $102,000 convertible promissory note dated October 12, 2015, to JSJ Investments Inc. The loans, together with interest at 12% per year, are payable on December 30, 2016. We may prepay the loans at any time. If the loans are repaid on or before September 30, 2016, the principal amount, which is being repaid, will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount, which is being repaid will increase by 15%. As of December 31, 2016, the loans were not repaid, when they were due, per the terms of the notes, and thus, the principal balance of the notes at that date was increased to $57,500 in the aggregate, with the addition to the principal balance charged to interest expense. Historically, Messrs. Blackmon, Verzura and Ruby, who are officers and directors of the Company, have paid obligations and expenses on behalf of the Company from their own individual, personal funds. Such payments have been recorded in the consolidated balance sheets as a component of Notes payable to and advances from officers and directors. During year ended December 31, 2018, Mr. Blackmon, the Chairman, Chief Executive Officer and President of the Company paid $419,729, net of reimbursements, of obligations and expenses of the Company from his own personal funds. These payments have been recorded in the consolidated balance sheets as a component of Notes payable to and advances from officers and directors. On July 1, 2018, we elected to convert all accrued and unpaid wages owed to Messrs. Blackmon, Verzura, and Ruby in the aggregate amount of $310,408 as notes payable to them. Thus, $310,408 is classified as Notes Payable for Advances from and Prior Wages Payable to Officers and Directors on the consolidated balance sheet of the Company at December 31, 2018. Interest on the notes is at a rate of 15% for the principal amount due Mr. Blackmon, and at a rate of 12.5% for on the principal amount owed Messrs. Verzura and Ruby. Effective March 21, 2019, Tony Verzura resigned as an officer and director of the Company.

ARBITRATION AND LITIGATION RESE

ARBITRATION AND LITIGATION RESERVE	12 Months Ended
	Dec. 31, 2018
Loss Contingency [Abstract]
ARBITRATION AND LITIGATION RESERVE	NOTE 16 – ARBITRATION AND LITIGATION RESERVE On May 8, 2018, H2, LLC (“H2”) and the Company executed a letter of intent formalizing their intent to enter into a joint venture. The parties subsequently made monetary advances in anticipation of formalizing the joint venture through a definitive agreement. However, the joint venture was never formalized, and the letter of intent was terminated pursuant to its terms. Under the terms of the provisions in the letter of intent that survived its termination, the Company has the option to either provide H2 with 25% of the industrial hemp seeds purchased with $650,000 advanced by H2, or to refund the $650,000 advanced by H2. Pursuant to another provision in the letter of intent that survived termination, disputes are to be resolved via arbitration in Denver, Colorado. On August 10, 2018, H2 filed a lawsuit in the state of California naming the Company, as well as, naming Earnest Blackmon, our Chairman of the Board and Chief Executive Officer, and John Walsh, our Treasurer and Principal Accounting Officer. The lawsuit asserts various claims, including rescission of any purported contract or joint venture and asks for $16,500,000 in damages. Our counsel and Management believe the suit is without merit, and we will vigorously defend against the lawsuit. We filed with the court a motion to compel arbitration and stay the litigation against Mr. Blackmon and Mr. Walsh. On December 20, 2018, the court granted our motion and ordered H2 to arbitrate its dispute with the Company in Denver, Colorado, and stayed the litigation against Mr. Blackmon and Mr. Walsh pending the arbitration. The Company and H2 are currently in discussions regarding resolution of the dispute either via arbitration or by agreement. On July 30, 2018, the Company filed a complaint for patent infringement and a demand for jury trial against Pure Hemp Collective Inc. (“Pure Hemp”) in the United States District Court for the District of Colorado. The Company contends that Pure Hemp has willfully and directly infringed the Company’s 9730911 Patent and seeks damages from Pure Hemp, among other relief. On October 29, 2018, Pure Hemp filed its answer, defenses and counterclaims, in which Pure Hemp contends the 9730911 Patent is not infringed by Pure Hemp and is invalid and unenforceable. Pure Hemp has also asserted a counterclaim under the Sherman Act against the Company in which it alleges the lawsuit is objectively baseless and requests the court enter an order awarding it its costs and attorneys’ fees as well as treble damages. The Company believes the Sherman Act counterclaim has no merit, and it is impossible to quantify the amount of any alleged damages allegedly suffered by Pure Hemp, or what its costs and fees in this case will be. The case is currently pending in the United States District Court for the District of Colorado.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 17 – STOCKHOLDERS’ EQUITY Preferred Stock On July 18, 2017, the Board of Directors adopted a resolution creating a series of Preferred Shares, no par value per share, designated as the Series A Preferred Shares. We subsequently issued 2,000 shares of our Series A Preferred Shares for $2,200 to our officers and directors. On March 20, 2019, we issued 2,000 additional shares of our Series A Preferred Shares to two officers and directors. Each preferred share is entitled to 15,000 votes on all matters submitted to the vote of our shareholders, is entitled to an annual dividend of $0.05 per share when, as, and if declared by our directors, and is convertible at any time, at the option of the holder of the preferred shares, into one share of our common stock. The holders of our Series A Preferred Shares have 15,000 votes for each share of the Series A Preferred Shares. Equity offerings February 14, 2018, we sold 65,440 shares of our common stock to an accredited investor for $57,083. Such shares were valued at $76,798 based on the previous trading day’s closing price. The difference between the proceeds received of $57,083 and the value of our common stock of $76,798 was recorded as loss on the issuance of common stock. August 20 2018, we sold 27,359 shares of our common stock to an accredited investor for $10,000. Such shares were valued at $13,249 based on the previous trading day’s closing price. The difference between the proceeds received of $10,000 and the value of our common stock of $13,249 was recorded as loss on the issuance of common stock. August 31, 2018, we sold 100,000 shares of our common stock to an accredited investor for $51,500. Such shares were valued at $62,750 based on the previous trading day’s closing price. The difference between the proceeds received of $51,500 and the value of our common stock of $62,750 was recorded as loss on the issuance of common stock. Common Stock Issued for Services On December 31, 2018, we issued 251,497 shares of common stock valued at $75,700, based on the previous trading day’s closing price, as annual incentive bonuses for certain employees. We recorded the $75,700 value of the common stock as share-based compensation expense and included this in general and administrative expenses in our consolidated statements of operations. At various times throughout the year ended December 31, 2018, we issued 50,000 shares of our common stock valued at $36,156 for marketing services, and we recorded the value of the shares as share based compensation and recorded this in marketing, advertising and new business development expenses in our consolidated statements of operations. At various times throughout the year ended December 31, 2018, we issued 310,000 shares of our common stock valued at $223,996 for legal services, and we recorded the value of the shares as share based compensation and in legal, accounting and new business development in our consolidated statements of operations. At various times throughout the year ended December 31, 2018, we issued 363,163 shares of our common stock valued at $297,400 as compensation to employees, and we recorded the value of the shares as share based compensation, which we recorded in general and administrative expenses in our consolidated statements of operations. On December 31, 2018, we issued 147,227 shares of common stock valued at $96,000, based on the applicable previous trading day’s closing price, as a component of employee compensation. We recorded the $96,000 value of the common stock as share-based compensation expense and included this in general and administrative expenses in our consolidated statements of operations. Common Shares Issued for Equity Funding Line In connection with a $10,000,000 equity funding line entered into on December 28, 2016, we received proceeds of $1,380,830 and issued 1,285,762 of our common shares to Tangiers Global, LLC (“Tangiers”) during the year ended December 31, 2018. We recorded a loss of $536,345 of on the issuance of the 1,285,762 shares, which has been recorded a Loss on issuance of common stock in our consolidated statement of operations. In connection with a $9,000,000 equity funding line entered into on January 23, 2018 we received proceeds of $4,710,259 and issued 9,000,000 of our common shares to Tangiers during the year ended December 31, 2018. We recorded a loss of $1,421,545 of on the issuance of the 9,000,000 shares, which has been recorded a Loss on issuance of common stock in our consolidated statement of operations. Common Shares Issued Upon Conversion of Notes On September 29, 2018, we issued 1,956,522 shares of our common stock to Tangiers upon the conversion of a $600,000 convertible note. We recognized a loss of $466,744 on the conversion of this convertible note for the year ended December 31, 2018. On September 29, 2018, we issued 1,121,279 shares of our common stock to Tangiers upon the conversion of a $288,750 convertible note. We recognized a loss of $358,323 on the conversion of this convertible note for the year ended December 31, 2018. Warrants: The following table summarizes our share warrants outstanding as of December 31, 2018 and 2017: Year Ended December 31, 2018 2017 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,209,025 $ 0.21 $ 1,551,356 $ 0.18 Warrants issued to consultants 100,008 0.89 132,669 0.89 Cashless warrants issued upon conversion of Slainte note — — — Warrants exercised — — (475,000 ) — Expired — — — — Warrants outstanding, end of period 1,309,033 $ 0.27 1,209,025 $ 0.21 Warrants exercisable, end of period 1,309,033 $ 0.27 1,209,025 $ 0.21 The weighted-average remaining contractual life for warrants outstanding and exercisable at December 31, 2018 and December 31, 2017, is 3.6 years and 3.0 years, respectively; and the aggregate intrinsic value of warrants outstanding and exercisable at December 31, 2018 and December 31, 2017 is $0. 132,669 warrants issued during the year 2017, respectively, were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % 100,008 warrants issued during the year ended December 31, 2018 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % 2014 Equity Incentive Plan On November 20, 2014, our board of directors approved our 2014 Stock Incentive Plan (the “Plan”) and the Plan became effective on November 19, 2015. The Plan provides officers, directors, selected employees and outside consultants an opportunity to acquire or increase a direct ownership interest in our operations and future success. Our board of directors currently administers the Plan and makes all decisions concerning which officers, directors, employees and other persons are granted awards, how many to grant to each recipient, when awards are granted, the terms and conditions applicable to awards, how the Plan should be interpreted, whether to amend or terminate the Plan and whether to delegate administration of the Plan to a committee. A maximum of 4,000,000 common shares are subject to the Plan. The Plan provides for the grant of stock options, stock awards, restricted stock units and stock appreciation rights. Stock options may be non-qualified stock options or incentive stock options except that stock options granted to outside directors, consultants or advisers providing services to us shall in all cases be non-qualified stock options. The Plan will terminate on November 20, 2024, unless the administrator terminates the Plan earlier. As of December 31, 2018, no common shares were available for issue under the Plan. 2017 Equity Incentive Plan On May 31, 2017, our board of directors approved our 2017 Stock Incentive Plan (the “Plan”) and the Plan became effective on May 31, 2017. The Plan provides officers, directors, selected employees and outside consultants an opportunity to acquire or increase a direct ownership interest in our operations and future success. Our board of directors currently administers the Plan and makes all decisions concerning which officers, directors, employees and other persons are granted awards, how many to grant to each recipient, when awards are granted, the terms and conditions applicable to awards, how the Plan should be interpreted, whether to amend or terminate the Plan and whether to delegate administration of the Plan to a committee. A maximum of 6,000,000 common shares are subject to the Plan. The Plan provides for the grant of stock options, stock awards, restricted stock units and stock appreciation rights. Stock options may be non-qualified stock options or incentive stock options except that stock options granted to outside directors, consultants or advisers providing services to us shall in all cases be non-qualified stock options. The Plan will terminate on May 31, 2027, unless the administrator terminates the Plan earlier. As of December 31, 2018, 900,342 common shares were available for issue under the Plan. 2018 Equity Incentive Plan On January 31, 2018, our board of directors approved our 2018 Stock Incentive Plan (the “Plan”) and the Plan became effective on January 31, 2018. On June 21, 2018, our board of directors amended the Plan to increase the maximum number of our shares of common shares subject to the plan from 12,500,000 to 25,000,000. The Plan provides officers, directors, selected employees and outside consultants an opportunity to acquire or increase a direct ownership interest in our operations and future success. Our board of directors currently administers the Plan and makes all decisions concerning which officers, directors, employees and other persons are granted awards, how many to grant to each recipient, when awards are granted, the terms and conditions applicable to awards, how the Plan should be interpreted, whether to amend or terminate the Plan and whether to delegate administration of the Plan to a committee. The Plan provides for the grant of stock options, stock awards, restricted stock units and stock appreciation rights. Stock options may be non-qualified stock options or incentive stock options except that stock options granted to outside directors, consultants or advisers providing services to us shall in all cases be non-qualified stock options. The Plan will terminate on January 31, 2028, unless the administrator terminates the Plan earlier. As of December 31, 2018, 3,941,040 common shares were available for issue under the Plan. Stock Options On January 12, 2016, we awarded 1,050,000 stock options to each of Messrs. Blackmon and Verzura and 980,000 stock options to Mr. Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and give the option holder the right to purchase shares of our common stock at $0.20 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.20 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.20 Exercise price $ 0.20 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % On February 28, 2018, we awarded 6,000,000 stock options to various employees under our 2017 Stock Incentive Plan. Of these options, 5,125,000 were fully vested at the time of grant with the remaining 875,000 vesting quarterly through December 31, 2019. The awarded options give the option holder the right to purchase shares of our common stock at $1.08 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.91 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 1.05 Exercise price $ 1.08 Risk free interest rate 2.8 % Expected term (years) 5-10 Expected volatility 197 % Expected dividends 0 % The total grant-date fair value of these options was approximately $6,146,000. Stock-based compensation expense related to these stock options included in operating expenses for the twelve months ended December 31, 2018 was approximately $5,785,348. On June 29, 2018, we awarded 14,195,000 stock options to various employees under our 2018 Stock Incentive Plan. Of these options, 13,250,000 were fully vested at the time of grant with the remaining 945,000 vesting quarterly through July 1, 2022. The awarded options give the option holder the right to purchase shares of our common stock at $0.705 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.59 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.705 Exercise price $ 0.705 Risk free interest rate 2.73 - 2.81 % Expected term (years) 5 Expected volatility 427% - 505 % Expected dividends 0 % The total grant-date fair value of these options was approximately $9,711,400. Stock-based compensation expense related to these stock options included in operating expenses for the twelve months ended December 31, 2018 was approximately $9,104,999. The following table summarizes our stock options outstanding as of both December 31, 2018 and 2017, respectively: Number of Weighted Weighted Stock options outstanding at December 31, 2016 3,680,000 8.9 $ 0.28 Issued 3,957,500 $ Exercised (1,000,000 ) — — Expired — — — Stock options outstanding at December 31, 2017 6,637,500 8.7 $ 0.57 Issued 20,199,800 9.3 0.43 Exercised — — — Expired — — — Stock options outstanding at December 31, 2018 26,837,300 9.2 $ 0.42 Stock options exercisable at December 31, 2018 25,162,500 9.0 $ 0.41 The total price to exercise all outstanding stock options is $11,051,639. The weighted-average remaining contractual life for stock options outstanding and exercisable at December 31, 2018, is 8.7 years, and the aggregate intrinsic value of options outstanding and exercisable at December 31, 2018 is $0. On July 25, 2018, we repriced the exercise price per share from $1.08 to $0.58 per share for the stock options to purchase 6,000,000 shares of our common stock that were granted on March 28, 2018 and repriced the exercise price per share from $0.705 to $0.58 per share for the stock options to purchase 14,195,000 of our common stock that were granted on June 29, 2018. No adjustment to shared-based compensation in the consolidated financial statements for the year ended December 31, 2018 was necessary as a result of the repricing of the stock options. On August 17, 2018, we repriced the exercise price per share (i) from $0.70 to $0.43 for per share for stock options to purchase 600,000 shares of our common stock that were granted on January 1, 2015 (ii) from 0.56 to $0.43 for per share for stock options to purchase 2,900,000 shares of our common stock that were granted on January 12, 2016 (iii) from $0.92 to $0.43 for 57,500 per share for stock options to purchase 57,500 shares of our common stock that were granted on July 27, 2017 (iv) from $0.875 to $0.43 per share for stock options to purchase 1,000,000 shares of our common stock that were granted on December 8, 2017 (v) from $.058 to $0.43 per share for stock options to purchase 6,000,000 shares of our common stock that were granted on March 28, 2018 and (vi) from $0.58 to $0.43 per share for stock options to purchase 14,195,000 of our common stock that were granted on June 29, 2018. No adjustment to shared-based compensation in the consolidated financial statements for the year ended December 31, 2018 was necessary as a result of the repricing of the stock options.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 18 – SHARE-BASED COMPENSATION Share-based Compensation We recognize share-based compensation expense in cost of revenues, sales and marketing expenses, R&D expenses, general and administrative expenses, and other income and expenses, based on the fair value of common shares issued for services. In addition, we accrue share-based compensation expense for estimated share-based awards earned during the years ended December 31, 2018 and 2017, under our 2017 Equity Incentive Plan and our 2018 Equity Incentive Plan. Share-based compensation expense for the years ended December 31, 2018 and 2017 is, as follows: December 31, 2018 2017 Warrants issued for consulting and other services $ 102,640 $ 249,835 Common stock issued for accounts payable and accrued expenses — 93,002 Common stock issued for services 495,151 — Common stock issued for advisory board fees 96,000 113,336 Common stock issued as compensation to employees 138,101 170,233 Stock options issued to officers and directors and employees 14,890,347 2,660,159 $ 15,722,239 $ 3,286,565

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 19 – INCOME TAXES The Internal Revenue Code (“IRC”) allows net operating losses (“NOL's”) to be carried forward and applied against future profits for a period of twenty years. The change of ownership following our merger with MySkin may limit our ability to utilize these NOLs under the terms of IRC Section 381. We did not provide any current or deferred federal income tax provision or benefit for any of the periods presented in our consolidated financial statements because we have experienced losses since our inception. When it is more likely than not, that a tax asset cannot be realized through future income, we must record an allowance against any potential future tax benefit. We provided a full valuation allowance against our net deferred tax assets, consisting of net operating loss carry forwards, because we determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carry forward periods. We have not taken a tax position that, if challenged, would have a material effect on our consolidated financial statements for the years ended December 31, 2018 and 2017, as defined under ASC 740. We did not recognize any adjustment to our liability for uncertain tax positions and therefore did not record any adjustment to the beginning balance of our accumulated deficit on our consolidated balance sheets. Our provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences for the periods presented are as follows: Years Ended December 31, 2018 2017 Statutory U.S. federal tax rate 21 % 39 % Effect of increase in valuation allowance (21 %) (39 %) — % — % Changes in our cumulative net deferred tax assets consist of the following: December 31, 2018 2017 Net loss carry-forward $ 11,042,420 $ 4,923,492 Valuation allowance (11,042,420 ) (4,923,492 ) $ — $ — A reconciliation of our income taxes computed at the statutory rate is as follows: Years Ended December 31, 2018 2017 Tax benefit at statutory rate $ 2,318,908 $ 2,023,555 Valuation allowance (2,318,908 ) (2,023,555 ) $ — $ —

SIGNIFICANT CUSTOMER INFORMATIO

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY	12 Months Ended
	Dec. 31, 2018
Risks and Uncertainties [Abstract]
SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY	NOTE 20 – SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Year Ended December 31, 2018 2017 Customer A 12% 98% Customer B 12% 2% Customer C 8% — % Percentage of Accounts Receivable: Year Ended December 31, 2018 2017 Customer D 98% —% Customer E 2% —% Customer F —% —% The following tables show significant concentrations in our expenses and accounts payable for the periods indicated: Percentage of Expenses: Year Ended December 31, 2018 2017 Vendor A 7% 26% Vendor B 6% 21% Vendor C 5% 14% Percentage of Accounts Payable: Year Ended December 31, 2018 2017 Vendor D 25% 33% Vendor E 22% 26% Vendor F 7% 26%

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 21 – COMMITMENTS AND CONTINGENCIES Contractual Obligations and Commercial Commitments Clinical Trial Funding Commitment On August 3, 2018, our 95% owned subsidiary, Prana Therapeutics, Inc. (“PTI”) received approval of an Investigational New Drug (“IND”) application from the Department of Health and Human Services’ Food and Drug Administration for a clinical investigation for breast cancer of PTI’s licensed flagship product, Epidiferphane™ (EDP™). We have committed to spend approximately $300,000 during 2019 and 2020 to fund phase I and phase II clinical trials in connection with the IND approval. Clinical Trial Agreement Under the terms of an agreement dated November 11, 2017, we committed to pay the costs to perform clinical trials with The University of the West Indies through the Topical Metabolism Research Unit of the Caribbean Institute for Health Research located in Kingston, Jamaica. The clinical trial was completed in February 2019, and thus, a final instalment of $51,182 is due and payable to the University of West Indies. We have agreed to reimburse The University of the West Indies for care and treatment of patients suffering adverse reactions or injury sustained by a patient, as a direct result of the clinical trial. Research Laboratory In October 2017, our 95% owned subsidiary, Prana Therapeutics, Inc (“PTI”), entered into a research agreement with the University of Florida Trustees (“UFT”). Under the terms of the research agreement PTI committed to pay UFT $303,544 in four (4) installments, of which $75,886 is owed as of December 31, 2018. Additionally, PTI is negotiating a research agreement with UFT for 2019 and 2020. Under the terms of the draft research agreement, PTI would pay UFT $700,000 in 2019 and $900,000 in 2020 in varying quarterly installments, beginning in April 2019. Hemp Crop Under Cultivation We entered into a farm lease for acreage on which the Company is growing an industrial hemp crop. The rent for the acreage under the terms of the farm lease is in an amount per acre predicated upon the total weight in pounds of industrial hemp flower harvested at a rate of $2 per pound (dry weight, after thrashing to remove seeds), with a minimum of $1,000 per acre. The rent is payable in three (3) installments; (i) one third on November 15, 2018, (ii) one third on December 31, 2018 and (iii) the remainder of all rents is payable on February 15, 2019. At December 31, 2018, $380,000 is outstanding under the terms of the farm lease and is included in Accounts payable on our Consolidated Balance Sheets. Industrial Hemp Crop Under Cultivation – Transaction with and Commitment to a Related Party Approximately 30% of the farm acreage, on which we were growing our industrial hemp crop, is contractually controlled by a joint venture, NEC Agri Services, LLC (“NEC”). Our Principal Financial Officer is one of the managing members and owners of NEC. In exchange for supplying the farm acreage along with certain farm equipment, infrastructure and our lead farmer and farm management, the Company agreed to pay NEC a stipulated dollar amount per weight in pounds of industrial hemp flower harvested on the NEC farm acreage (dry weight after thrashing for the removal of seeds), reduced by a ratable allocation per acre of total farming costs for the industrial hemp crop under cultivation. We believe the stipulated dollar amount per weight in pounds is commensurate to the fair market value that we could have received from an independent farmer and land owner.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 22 – SUBSEQUENT EVENTS On February 11, 2019, we issued a note to an unaffiliated third party, Tangiers Global, LLC, in the amount of $1,575,000 (“Note”), the terms of which allow us to draw down on the Note in tranches, upon our election. We drew down $500,000 on the Note, net of a debt discount of $25,000, the proceeds of which were used to purchase equipment and for general working capital purposes. The debt discount on the Note is amortized on a straight-line basis from the issue date, which approximates the effective interest rate method, over the term of the note, and this amortization will be included in interest expense in our consolidated statements of operations. On March 20, 2019, we issued 1,500 additional shares of our Series A Preferred Shares to two officers and directors. Tony Verzura, who resigned as an officer and director of the Company effective March 21, 2019, agreed to the cancellation of his 500 shares of preferred stock. In accordance with ASC 855-10 we have analyzed our operations subsequent to December 31, 2018 to the date these consolidated financial statements were issued, and have determined that, other than as disclosed above, we do not have any material subsequent events to disclose in these consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation At March 31, 2017, we concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017. PTI was purchased on July 14, 2017, and its assets and liabilities are included in the consolidated balance sheets at December 31, 2018 and 2017, and their results of operations are included in the consolidated financial statements for the years ended December 31, 2018 and 2017.
Use of Estimates	Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at December 31, 2018, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the years ended December 31, 2018 and 2017.
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable, Net	Accounts Receivable, Net
Inventory	Inventory –
Property, Plant and Equipment, net	Property, Plant and Equipment, net
Granted Patents, Net	Granted Patents, Net –
Intangible Assets	Intangible Assets –
Long-Lived Assets Impairment Assessment	Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of December 31, 2018 or December 31, 2017.
Goodwill	Goodwill fl –
Purchase Price Allocation	Purchase Price Allocation – “ Business Combinations ” Fair Value Measurements and Disclosures
Deferred Revenue	Deferred Revenue
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Revenue from Contracts with Customers. We have licensed Prana Hemp Prana Hemp Prana Hemp Prana Hemp Prana Hemp Revenue from Contracts with Customers.
Cost of Revenues	Cost of Revenues
Research and Development Expenses	Research and Development Expenses
General and Administrative Expenses	General and Administrative Expenses
Stock-Based Compensation	Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the years ended December 31, 2018 or 2017, respectively.
Commitments and Contingencies	Commitments and Contingencies – Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Net Loss Per Share	Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Years Ended December 31, 2018 2017 Warrants to purchase common stock 1,309,033 1,209,025 Stock options 26,837,300 6,637,500 28,146,333 7,846,525
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss)
Concentration of Credit Risk	Concentration of Credit Risk
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued an ASU No. 2016-02 Leases (Topic 842) In June 2018, the FASB issued updated ASU 2018-07 – Compensation – Stock Compensation (Topic 718)
Reclassification	Reclassification

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Years Ended December 31, 2018 2017 Warrants to purchase common stock 1,309,033 1,209,025 Stock options 26,837,300 6,637,500 28,146,333 7,846,525

DUE FROM RELATED PARTY (Tables)

DUE FROM RELATED PARTY (Tables)	12 Months Ended
	Dec. 31, 2018
Receivable From Related Party Tables Abstract
Schedule of Amounts Due From Related Parties	Amounts due from related from related parties include the following: December 31, 2018 2017 Advesa, Inc. $ 42,349 $ — NutriMed, LLC 44,622 — $ 86,971 $ —

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	12 Months Ended
	Dec. 31, 2018
Leases [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum payments for these leases are: For the twelve Months Ending December 31, 2019 2020 2021 2022 2023 $322,101 $304,332 $251,961 $234,321 $113,417

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Tables Abstract
Schedule of Inventory	At December 31, 2018 and 2017, our inventory was, as follows: December 31, 2018 2017 Raw materials $ 1,813,880 $ 15,000 Work-in-process 666,845 — Finished goods 71,393 28,200 $ 2,552,118 $ 43,200

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment, Net [Abstract]
Schedule of Property and Equipment	December 31, 2018 2017 Cost of construction in process - extraction facility Weldona, Colorado extraction facility: Equipment and leasehold improvements $ — $ 647,947 Mead, Colorado extraction facility Equipment and leasehold improvements 1,743,223 — Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 75,000 Leasehold improvements - cultivation 118,964 109,750 $ 1,937,187 $ 832,697 December 31, 2018 2017 Extraction facility, laboratory equipment, and office furniture and fixtures Weldona extraction facility Equipment and machinery $ 1,269,734 $ — Furniture and fixtures 64,955 — Leasehold improvements 237,581 — Transportation equipment 60,228 — Farm Equipment 531,245 — Golden, Colorado administrative offices: Furniture and fixtures 49,282 21,668 Leasehold improvements — 2,000 Transportation equipment 200,704 81,667 Golden, Colorado industrial hemp laboratory - equipment 39,944 34,651 Remote laboratory equipment 99,220 99,220 2,552,893 239,206 Accumulated amortization and depreciation (433,148 ) (39,385 ) $ 2,119,745 $ 199,821

PURCHASE OF PRANA THERAPUETIC_2

PURCHASE OF PRANA THERAPUETICS, INC. (Tables)	12 Months Ended
	Dec. 31, 2018
Purchase Of Prana Therapuetics Inc.Tables Abstract
Schedule of allocation of purchase price	The purchase price for Prana was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. The allocation of the purchase price was, as follows: December 31, Patents $ 52,596 Net assets 522,761 Goodwill 4,495,143 Total $ 5,070,500

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	Our accrued expenses consist of: December 31, 2018 2017 Accrued wages and related expenses $ 126,345 $ 10,184 Accrued interest expense 2,572 — Other accrued expenses 10,186 — Total accrued expenses $ 139,103 $ 10,184

DEFERRED REVENUE (Tables)

DEFERRED REVENUE (Tables)	12 Months Ended
	Dec. 31, 2018
Deferred Revenue Disclosure [Abstract]
Schedule of deferred revenue	Our deferred revenue consists of: December 31, 2018 2017 Deferred revenue – WeedMD $ 23,750 $ 203,750 Less – current portion (23,750 ) (180,000 ) Deferred revenue, net of current portion $ — $ 23,750

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Payable [Abstract]
Schedule of Convertible Promissory Notes Issued	The following table summarizes the Note outstanding as of December 31, 2018 and 2017: December 31, Issue Date Security Maturity Date Interest Rate Draws Under the Note 2018 2017 11/05/2018 Unsecured 5/04/2019 5% First Tranche $ 525,000 $ — 12/05/2018 Unsecured 6/3/2019 5% Second Tranche 525,000 — 12/26/2018 Unsecured 6/24/2019 5% Third Tranche 525,000 — Less unamortized discount (62,917 ) — $ 1,512,083 $ —

NOTES PAYABLE TO AND ADVANCES_2

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Payable To And Advances From Officers And Directors Tables Usd
Notes payable to and advance from officers and directors	Notes payable to and advance from officers and directors consisted of the following, at December 31, 2018 and 2017: December 31, 2018 2017 Note payable to Earnie Blackmon, an officer and director $ 840,807 $ 246,459 Note payable to Tony Verzura, an officer and director 160,247 14,889 Note payable to Chad Ruby, an office and director 154,382 — $ 1,155,436 $ 261,348

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2018
Summary of share warrants outstanding	The following table summarizes our share warrants outstanding as of December 31, 2018 and 2017: Year Ended December 31, 2018 2017 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,209,025 $ 0.21 $ 1,551,356 $ 0.18 Warrants issued to consultants 100,008 0.89 132,669 0.89 Cashless warrants issued upon conversion of Slainte note — — — Warrants exercised — — (475,000 ) — Expired — — — — Warrants outstanding, end of period 1,309,033 $ 0.27 1,209,025 $ 0.21 Warrants exercisable, end of period 1,309,033 $ 0.27 1,209,025 $ 0.21
Summary of stock options outstanding	The following table summarizes our stock options outstanding as of both December 31, 2018 and 2017, respectively: Number of Weighted Weighted Stock options outstanding at December 31, 2016 3,680,000 8.9 $ 0.28 Issued 3,957,500 $ Exercised (1,000,000 ) — — Expired — — — Stock options outstanding at December 31, 2017 6,637,500 8.7 $ 0.57 Issued 20,199,800 9.3 0.43 Exercised — — — Expired — — — Stock options outstanding at December 31, 2018 26,837,300 9.2 $ 0.42 Stock options exercisable at December 31, 2018 25,162,500 9.0 $ 0.41
Stock Options [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	We calculated the fair value of each option to be approximately $0.20 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.20 Exercise price $ 0.20 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % We calculated the fair value of each option to be approximately $0.91 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 1.05 Exercise price $ 1.08 Risk free interest rate 2.8 % Expected term (years) 5-10 Expected volatility 197 % Expected dividends 0 % We calculated the fair value of each option to be approximately $0.59 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.705 Exercise price $ 0.705 Risk free interest rate 2.73% - 2.81 % Expected term (years) 5 Expected volatility 427% - 505 % Expected dividends 0 %
Warrant [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	132,669 warrants issued during the year 2017, respectively, were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % 100,008 warrants issued during the year ended December 31, 2018 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 %

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of share-based compensation expense	We recognize share-based compensation expense in cost of revenues, sales and marketing expenses, R&D expenses, general and administrative expenses, and other income and expenses, based on the fair value of common shares issued for services. In addition, we accrue share-based compensation expense for estimated share-based awards earned during the years ended December 31, 2018 and 2017, under our 2017 Equity Incentive Plan and our 2018 Equity Incentive Plan. Share-based compensation expense for the years ended December 31, 2018 and 2017 is, as follows: December 31, 2018 2017 Warrants issued for consulting and other services $ 102,640 $ 249,835 Common stock issued for accounts payable and accrued expenses — 93,002 Common stock issued for services 495,151 — Common stock issued for advisory board fees 96,000 113,336 Common stock issued as compensation to employees 138,101 170,233 Stock options issued to officers and directors and employees 14,890,347 2,660,159 $ 15,722,239 $ 3,286,565

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of sources and tax effects of the differences for the periods	The sources and tax effects of the differences for the periods presented are as follows: Years Ended December 31, 2018 2017 Statutory U.S. federal tax rate 21 % 39 % Effect of increase in valuation allowance (21 %) (39 %) — % — %
Schedule of changes in cumulative net deferred tax assets	Changes in our cumulative net deferred tax assets consist of the following: December 31, 2018 2017 Net loss carry-forward $ 11,042,420 $ 4,923,492 Valuation allowance (11,042,420 ) (4,923,492 ) $ — $ —
Schedule of reconciliation of income taxes computed at the statutory rate	A reconciliation of our income taxes computed at the statutory rate is as follows: Years Ended December 31, 2018 2017 Tax benefit at statutory rate $ 2,318,908 $ 2,023,555 Valuation allowance (2,318,908 ) (2,023,555 ) $ — $ —

SIGNIFICANT CUSTOMER INFORMAT_2

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY (Tables)	12 Months Ended
	Dec. 31, 2018
Risks and Uncertainties [Abstract]
Schedule of significant concentrations risk	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Year Ended December 31, 2018 2017 Customer A 12% 98% Customer B 12% 2% Customer C 8% — % Percentage of Accounts Receivable: Year Ended December 31, 2018 2017 Customer D 98% —% Customer E 2% —% Customer F —% —% The following tables show significant concentrations in our expenses and accounts payable for the periods indicated: Percentage of Expenses: Year Ended December 31, 2018 2017 Vendor A 7% 26% Vendor B 6% 21% Vendor C 5% 14% Percentage of Accounts Payable: Year Ended December 31, 2018 2017 Vendor D 25% 33% Vendor E 22% 26% Vendor F 7% 26%

BUSINESS ORGANIZATION AND NAT_2

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) - USD ($)	Jul. 14, 2017	Mar. 31, 2014	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 26, 2014
Amount of payable owed to former officer and director, exchanged for assets sold		$ 15,000
Number of common shares issued in exchange for certain intellectual property		38,690,000
Total number of common shares previously outstanding, cancelled during period							41,690,000
Common stock, shares outstanding			77,467,980		62,862,066		43,620,000
Prana [Member]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Prana [Member] | Subscription Agreement [Member]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000			$ 50,000	$ 50,000	$ 50,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Jan. 02, 2019	Dec. 31, 2017
Allowance for doubtful accounts
Equity Method Investments, Percentage	20.00%
Goodwill	$ 4,838,603		$ 4,838,603
Purchase Price Allocation	5,070,500
Excess of purchase price over fair values of net tangible assets and intangible assets recorded as goodwill	4,731,729
Business development	$ 2,800,000
Subsequent Event [Member]
Operating lease assets		$ 1,100,000
Operating lease liabilities		$ 1,100,000
Maximum [Member]
Estimated useful lives	5 years
Estimated useful life	15 years
Minimum [Member]
Estimated useful lives	3 years
Estimated useful life	10 years
Patents [Member]
Estimated useful life	15 years
PTI [Member]
Equity Method Investments, Percentage	95.00%
Goodwill	$ 4,731,729
Purchase Price Allocation	$ 5,070,500
CRD [Member]
Equity Method Investments, Percentage	50.00%
Goodwill	$ 106,874

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	28,146,333	7,846,525
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	1,309,033	1,209,025
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	26,837,300	6,637,500

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
GOING CONCERN [Abstract]
Net loss (income)	$ 24,318,870	$ 6,203,604
Net cash used in operating activities	7,246,729	1,878,276
Working capital deficit	2,079,917
Accumulated deficit	$ 39,374,396	$ 15,269,845

DUE FROM RELATED PARTY (Schedul

DUE FROM RELATED PARTY (Schedule of Amounts Due from Related Parties) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Total due from related parties	$ 86,971
Revenue from related parties	197,032	182,323
Advesa [Member]
Related Party Transaction [Line Items]
Total due from related parties	42,349
NutriMed, LLC [Member]
Related Party Transaction [Line Items]
Total due from related parties	$ 44,622

OPERATING LEASES (Narrative) (D

OPERATING LEASES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)ft²a
Operating Leased Assets [Line Items]
Equity Method Investments, Percentage	20.00%
CRD [Member]
Operating Leased Assets [Line Items]
Equity Method Investments, Percentage	50.00%
Golden, Colorado Testing Lab [Member]
Operating Leased Assets [Line Items]
Lease expiration date	Oct. 31, 2020
Square footage of leased space | ft²	2,100
Basic rent per month	$ 2,161
Basic rent per month period two	$ 2,226
Mead, Colorado Extraction Facility [Member]
Operating Leased Assets [Line Items]
Lease expiration date	Aug. 31, 2019
Square footage of leased space | ft²	14,300
Basic rent per month	$ 12,596
Security deposit	$ 75,000
Administrative Offices and Hemp Laboratory - Golden, Colorado [Member]
Operating Leased Assets [Line Items]
Lease expiration date	Jul. 31, 2020
Square footage of leased space | ft²	9,882
Basic rent per month	$ 3,302
Basic rent per month period two	3,500
Basic rent per month period three	$ 3,800
Fort Morgan, Colorado Extraction and Cultivation Facility [Member]
Operating Leased Assets [Line Items]
Land subject to lease | a	5
Lease expiration date	Sep. 30, 2022
Square footage of leased space | ft²	40,000
Basic rent per month	$ 7,500
Jamaica Cultivation and Extraction Facility [Member]
Operating Leased Assets [Line Items]
Land subject to lease | a	28
Lease amount from father of directors and members	$ 1

OPERATING LEASES (Schedule of F

OPERATING LEASES (Schedule of Future Minimum Lease Payments) (Details)	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 322,101
2020	304,332
2021	251,961
2022	234,321
2023	$ 113,417

INVENTORY (Details)

INVENTORY (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory Abstract
Raw materials	$ 1,813,880	$ 15,000
Work-in-process	666,845
Finished goods	71,393	28,200
Inventory	$ 2,552,118	$ 43,200

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 400,907	$ 40,161
Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 393,763	$ 39,385

PROPERTY, PLANT AND EQUIPMENT_4

PROPERTY, PLANT AND EQUIPMENT, NET (Schedule of Property and Equipment) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	$ 1,937,187	$ 832,697
Extraction facility, laboratory equipment, and office furniture and fixtures	2,552,893	239,206
Accumulated amortization and depreciation	(433,148)	(39,385)
Cultivation facility and laboratory equipment and Office furniture and fixtures	2,119,745	199,821
Equipment and leasehold improvements [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility		647,947
Equipment and leasehold improvements [Member] | Mead, Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	1,743,223
Leasehold Improvements - Laboratory [Member] | Jamaica Cultivation and Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	75,000	75,000
Leasehold Improvements - Cultivation [Member] | Jamaica Cultivation and Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	118,964	109,750
Furniture and Fixture [Member] | Colorado Administrative Offices [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	49,282	21,668
Furniture and Fixture [Member] | Weldona extraction facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	64,955
Leasehold Improvements [Member] | Colorado Administrative Offices [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures		2,000
Leasehold Improvements [Member] | Weldona extraction facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	237,581
Furniture and Fixture [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	200,704	81,667
Furniture and Fixture [Member] | Weldona extraction facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	60,228
Golden, Colorado Hemp Laboratory - Equipment [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	39,944	34,651
Remote Laboratory Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	99,220	99,220
Machinery and Equipment [Member] | Weldona extraction facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	1,269,734
Farm Equipment [Member] | Weldona extraction facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	$ 531,245

PURCHASE OF PRANA THERAPUETIC_3

PURCHASE OF PRANA THERAPUETICS, INC. (Narrative) (Details) - Prana [Member] - USD ($)	Jul. 14, 2017	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Business Acquisition [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Shares issued in acquisition	400,000
Shares issued in acquisition, value	$ 200,000
Subscription Agreement [Member]
Business Acquisition [Line Items]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000		$ 50,000	$ 50,000	$ 50,000
Net assets acquired		$ 522,761

PURCHASE OF PRANA THERAPUETIC_4

PURCHASE OF PRANA THERAPUETICS, INC. (Schedule of Purchase Price Allocation) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 4,838,603	$ 4,838,603
Purchase Price Allocation	5,070,500
Prana [Member] | Subscription Agreement [Member]
Business Acquisition [Line Items]
Patents	52,596
Net assets	522,761
Goodwill	4,495,143
Purchase Price Allocation	$ 5,070,500

GRANTED PATENT (Details)

GRANTED PATENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Aug. 15, 2017
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ 9,795	$ 2,679
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful live	15 years
Amortization expense	$ 7,116	2,679
Accumulated amortization	$ 9,795	$ 2,679
Research, legal fees			$ 142,317

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details)	12 Months Ended
	Dec. 31, 2018
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	15 years
Design Marks and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
Accrued wages and related expenses	$ 126,345	$ 10,184
Accrued interest expense	2,572
Other accrued expenses	10,186
Total accrued expenses	$ 139,103	$ 10,184

INSTALLMENT LOANS PAYABLE (Deta

INSTALLMENT LOANS PAYABLE (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Installment loan payable		$ 57,799	$ 46,667
Installment One [Member]
Debt Instrument [Line Items]
Installment loan monthly payment	$ 955
Monthly payments being made to pay off loan in six months	$ 6,955
Term period	48 months
Installment Two [Member]
Debt Instrument [Line Items]
Installment loan monthly payment	$ 2,160
Monthly payments being made to pay off loan in six months	$ 6,500
Term period	36 months
48 Month Installment [Member]
Debt Instrument [Line Items]
Installment loan payable		0	46,667
36 Month Installment [Member]
Debt Instrument [Line Items]
Installment loan payable		$ 57,799	$ 0

DEFERRED REVENUE (Details)

DEFERRED REVENUE (Details) - USD ($)	Jun. 09, 2014	Dec. 31, 2014	Dec. 31, 2018	Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]
Deferred revenue			$ 23,750	$ 203,750
Less - current portion			(23,750)	(180,000)
Deferred revenue, net of current portion				$ 23,750
WeedMD RX Inc. (''WMD'') [Member]
Deferred Revenue Arrangement [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000
Fair value of securities recorded as deferred revenue	$ 893,750
Deferred revenue recognized per month			15,000
Total deferred revenue recognized		$ 150,000	$ 180,000

NOTE PAYABLE (Narrative) (Detai

NOTE PAYABLE (Narrative) (Details) - USD ($)	Feb. 11, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Proceeds from notes payable		$ 1,500,000
Amortization of debt discount		55,833	30,453
Interest expense		2,572	0
Accrued expenses		$ 2,572	0
Percentage of mandatory default amount payable		130.00%
Additional interest on mandatory default amount from date of issuance rate		12.00%
Percentage of common stock at conversion price		70.00%
Convertible note, amount converted		$ 310,401
Loss on conversion of note		(825,067)
Converted Note One [Member]
Debt Instrument [Line Items]
Convertible note, amount converted		600,000
Loss on conversion of note		466,744
Converted Note Two [Member]
Debt Instrument [Line Items]
Convertible note, amount converted		288,750
Loss on conversion of note		358,323
Unaffiliated third party [Member]
Debt Instrument [Line Items]
Proceeds from notes payable		$ 1,575,000
Tangiers [Member]
Debt Instrument [Line Items]
Percentage of common stock per share price		70.00%
Tangiers [Member] | Transaction One [Member]
Debt Instrument [Line Items]
Notes payable premium percentage		10.00%
Tangiers [Member] | Transaction Two [Member]
Debt Instrument [Line Items]
Notes payable premium percentage		20.00%
Tangiers [Member] | Transaction Three [Member]
Debt Instrument [Line Items]
Notes payable premium percentage		30.00%
Tangiers [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Proceeds from notes payable	$ 1,575,000
Interest Rate	5.00%

NOTES PAYABLE (Schedule of Conv

NOTES PAYABLE (Schedule of Convertible Promissory Notes Issued) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Less unamortized discount	$ (62,917)
Total of outstanding amount	1,512,083
Convertible note, amount converted	310,401
Loss on conversion of note	$ (825,067)
First Tranche [Member] | 2018 Convertible Notes [Member]
Issue Date	Nov. 5, 2018
Security	Unsecured
Maturity Date	May 4, 2019
Interest Rate	5.00%
Total principal outstanding	$ 525,000
Second Tranche [Member] | 2018 Convertible Notes [Member]
Issue Date	Dec. 5, 2018
Security	Unsecured
Maturity Date	Jun. 3, 2019
Interest Rate	5.00%
Total principal outstanding	$ 525,000
Third Tranche [Member] | 2018 Convertible Notes [Member]
Issue Date	Dec. 26, 2018
Security	Unsecured
Maturity Date	Jun. 24, 2019
Interest Rate	5.00%
Total principal outstanding	$ 525,000

NOTES PAYABLE TO AND ADVANCES_3

NOTES PAYABLE TO AND ADVANCES FROM OFFICERS AND DIRECTORS (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 30, 2018	Dec. 31, 2017	Dec. 30, 2017	Dec. 30, 2016	Apr. 06, 2016	Oct. 12, 2015
Related Party Transaction [Line Items]
Convertible note payable, related party		$ 1,155,436		$ 261,348
Principal balance increase					$ 57,500
Notes payable to and advances from officers and directors	$ 419,729
Notes payable	310,408
Earnie Blackmon [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	840,807		$ 246,459
Tony Verzura [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount						$ 25,000
Tony Verzura [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	160,247		14,889
Chad Ruby [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	$ 154,382
Ernest Blackmon [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount						$ 25,000
Debt instrument, interest rate	15.00%
Debt Instrument Fair Value of Warrants Issued Recorded as Unamortized Discount
Related Party Transaction [Line Items]
Convertible note payable, related party							$ 102,000
JSJ Investments Inc. [Member]
Related Party Transaction [Line Items]
Debt instrument, interest rate					12.00%
Messrs. Verzura and Ruby [Member]
Related Party Transaction [Line Items]
Debt instrument, interest rate	12.50%

ARBITRATION AND LITIGATION RE_2

ARBITRATION AND LITIGATION RESERVE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Loss Contingency [Abstract]
Arbitration settlement reserve	$ 650,000
Proceeds from proposed joint venture that was never formed	650,000
Lawsuit damages claims	16,500,000
Proceeds from proposed joint venture that was never formed - arbitration reserve	$ 650,000

STOCKHOLDERS' EQUITY (Equity Tr

STOCKHOLDERS' EQUITY (Equity Transactions Narrative) (Details) - USD ($)	Dec. 31, 2018	Sep. 29, 2018	Sep. 28, 2018	Aug. 31, 2018	Aug. 20, 2018	Feb. 14, 2018	Mar. 20, 2019	Jul. 18, 2017	Dec. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Proceeds from shares issued									$ 152,797	$ 208,982
Aggregate intrinsic value of warrants outstanding and exercisable	$ 0								$ 0	$ 0
Warrant issued									100,008	132,669
Proceeds from issuance of common stock									$ 6,091,090	$ 2,682,750
Stock issued during period for services									96,000	113,336
General and administrative									4,850,738	1,440,208
Convertible note, amount converted									310,401
Loss on conversion of note									(825,067)
Converted Note One [Member]
Class of Stock [Line Items]
Proceeds from issuance of common stock			$ 1,956,522
Convertible note, amount converted									600,000
Loss on conversion of note									466,744
Converted Note Two [Member]
Class of Stock [Line Items]
Proceeds from issuance of common stock		$ 1,121,279
Convertible note, amount converted									288,750
Loss on conversion of note									$ 358,323
Warrant [Member]
Class of Stock [Line Items]
Warrant issued									100,008	132,669
Preferred Class A [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Preferred stock dividend per share							$ 0.05
Preferred Stock, Voting Rights							Each preferred share is entitled to 15,000 votes on all matters submitted to the vote of our shareholders, is entitled to an annual dividend of $0.05 per share when, as, and if declared by our directors, and is convertible at any time, at the option of the holder of the preferred shares, into one share of our common stock. The holders of our Series A Preferred Shares have 15,000 votes for each share of the Series A Preferred Shares.
Preferred Class A [Member] | Officer and Director [Member]
Class of Stock [Line Items]
Proceeds from shares issued								$ 2,200
Number of shares issued during period								2,000
Preferred Class A [Member] | Officer and Director [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares issued during period							1,500
Common Stock [Member] | Accredited Investor [Member]
Class of Stock [Line Items]
Stock issued during period				$ 62,750	$ 13,249	$ 76,798
Number of shares issued during period				100,000	27,359	65,440
Proceeds from issuance of common stock				$ 51,500	$ 10,000	$ 57,083
Loss recognized on issuance of common stock				$ 62,750	$ 13,249	$ 76,798
Common Stock [Member] | Employees [Member]
Class of Stock [Line Items]
Stock issued during period for services	$ 75,700
Number of shares issued for services during period	251,497
General and administrative	$ 75,700
Common Stock [Member] | Marketing Services [Member]
Class of Stock [Line Items]
Stock issued during period for services									$ 36,156
Number of shares issued for services during period									50,000
Common Stock [Member] | Legal Services [Member]
Class of Stock [Line Items]
Stock issued during period for services									$ 223,996
Number of shares issued for services during period									310,000
Common Stock [Member] | Employee Compensation [Member]
Class of Stock [Line Items]
Stock issued during period for services	$ 96,000								$ 297,400
Number of shares issued for services during period	147,227								363,163
General and administrative	$ 96,000
Common Stock [Member] | Tangiers Global, LLC [Member] | $10,000,000 equity funding line [Member]
Class of Stock [Line Items]
Number of shares issued during period									1,285,762
Proceeds from issuance of common stock									$ 1,380,830
Loss recognized on issuance of common stock									$ 536,345
Common Stock [Member] | Tangiers Global, LLC [Member] | $9,000,000 equity funding line [Member]
Class of Stock [Line Items]
Number of shares issued during period									9,000,000
Proceeds from issuance of common stock									$ 4,710,259
Loss recognized on issuance of common stock									$ 1,421,545

STOCKHOLDERS' EQUITY (Common St

STOCKHOLDERS' EQUITY (Common Stock Issued For Services, Warrants) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Warrants outstanding, beginning of period	1,209,025	1,551,356
Warrants issued to consultant	100,008	132,669
Cashless issued upon conversion of Slainte note
Warrants exercised		(475,000)
Expired (in shares)
Warrants outstanding, end of period	1,309,033	1,209,025
Warrants exercisable at the end of the period (in shares)	1,309,033	1,209,025
Weighted Average Remaining Life (years)
Warrants outstanding, beginning of period	3 years 7 months 6 days	3 years
Warrants outstanding, end of period	3 years 7 months 6 days	3 years
Warrants exercisable at the end of the period	3 years 7 months 6 days	3 years
Weighted Average Exercise Price
Warrants outstanding, beginning of period (in dollars per share)	$ 0.21	$ 0.18
Issued (in dollars per share)	0.89	0.89
Exercised (in dollars per share)
Repurchased and cancelled (in dollars per share)
Expired (in dollars per share)
Warrants outstanding, end of period (in dollars per share)	0.27	0.21
Warrants exercisable at the end of the period (in dollars per share)	$ 0.27	$ 0.21

STOCKHOLDERS' EQUITY (Schedule

STOCKHOLDERS' EQUITY (Schedule of Assumptions on Date of Valuation Utilizing for Fair Value of Warrants) (Details) - $ / shares	Jan. 12, 2016	Feb. 28, 2018	Jun. 29, 2018	Dec. 31, 2018	Dec. 31, 2017
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)				$ 0.16	$ 0.16
Risk free interest rate (as a percent)				1.01%	1.01%
Expected term (years)				5 years	5 years
Expected volatility (as a percent)				322.00%	322.00%
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)				$ 2.18	$ 2.18
Exercise price (in dollars per share)				$ 0.18	$ 0.18
Risk free interest rate (as a percent)				1.37%	1.37%
Expected volatility (as a percent)				504.00%	504.00%
Expected dividends (as a percent)				0.00%	0.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)	$ 0.20	$ 1.05	$ 0.705
Exercise price (in dollars per share)	$ 0.20	$ 1.08	$ 0.705
Risk free interest rate (as a percent)	1.98%	2.80%
Expected term (years)	10 years		5 years
Expected volatility (as a percent)	173.00%	197.00%
Expected dividends (as a percent)	0.00%	0.00%	0.00%
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate (as a percent)			2.73%
Expected term (years)		5 years
Expected volatility (as a percent)			427.00%
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate (as a percent)			2.81%
Expected term (years)		10 years
Expected volatility (as a percent)			505.00%

STOCKHOLDERS' EQUITY (Schedul_2

STOCKHOLDERS' EQUITY (Schedule of stock option activity) (Details) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Stock options outstanding, beginning of period	6,637,500	3,680,000
Issued	20,199,800	3,957,500
Exercised		(1,000,000)
Expired
Stock options outstanding, end of period	26,837,300	6,637,500	3,680,000
Stock options exercisable, end of period	25,162,500
Weighted Average Exercise Price
Stock options outstanding, beginning of period	$ 0.57	$ 0.28
Issued	0.43
Exercised
Expired
Stock options outstanding, end of period	0.42	$ 0.57	$ 0.28
Stock options exercisable, end of period	$ 0.41
Weighted Average Remaining Life (Years)
Stock options outstanding, end of period	9 years 2 months 12 days	8 years 8 months 12 days	8 years 10 months 25 days
Stock options exercisable, end of period	9 years	9 years 3 months 19 days

STOCKHOLDERS' EQUITY (Stock Opt

STOCKHOLDERS' EQUITY (Stock Option Activity) (Narrative) (Details) - USD ($)	1 Months Ended			12 Months Ended
	Aug. 17, 2018	Jul. 25, 2018	Jun. 29, 2018	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2018	Dec. 31, 2016	Jan. 12, 2016	Jan. 12, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options compensation				$ 14,890,347	$ 2,660,159
2014 Stock Incentive Plan [Member] | Mr. Ruby [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awarded stock options									$ 980,000
Common stock, per share value									$ 0.20
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awarded stock options								$ 1,050,000
Stock options				26,837,300	6,637,500		3,680,000
Fair value of options			9,711,400	6,146,000
Weighted-average remaining contractual life for stock options outstanding and exercisable				9 years	9 years 3 months 19 days
Aggregate intrinsic value of options outstanding and exercisable				$ 0
Option vested				5,125,000
Stock options compensation			$ 9,104,999	$ 5,785,348
Total price to exercise all outstanding stock options				$ 11,051,639
Stock options to purchase common stock		6,000,000
Stock Options [Member] | Granted on June 29, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	14,195,000
Stock Options [Member] | Granted on January 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	600,000
Stock Options [Member] | Granted on January 12, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	2,900,000
Stock Options [Member] | Granted on July 27, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	57,500
Stock Options [Member] | Granted on December 8, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	1,000,000
Stock Options [Member] | Granted on March 28, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	6,000,000
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price		$ 1.08	$ 0.705
Stock Options [Member] | Minimum [Member] | Granted on June 29, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.58
Stock Options [Member] | Minimum [Member] | Granted on January 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.70
Stock Options [Member] | Minimum [Member] | Granted on January 12, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.56
Stock Options [Member] | Minimum [Member] | Granted on July 27, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.92
Stock Options [Member] | Minimum [Member] | Granted on December 8, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.875
Stock Options [Member] | Minimum [Member] | Granted on March 28, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.058
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price		$ 0.58	$ 0.58
Stock Options [Member] | Maximum [Member] | Granted on June 29, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on January 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on January 12, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on July 27, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on December 8, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on March 28, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.43
Stock Options [Member] | Vesting through December 31, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vested				875,000
Stock Options [Member] | Vesting quarterly through July 1, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vested				945,000
Stock Options [Member] | 2017 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awarded stock options						$ 6,000,000
Stock Options [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awarded stock options			$ 14,195,000
Option vested				13,250,000

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Warrants issued for consulting and other services	$ 102,640	$ 249,835
Common stock issued for accounts payable and accrued expenses		93,002
Common stock issued for services	495,151
Common stock issued for advisory board fees	96,000	113,336
Common stock issued as compensation to employees	138,101	170,233
Stock options issued to officers and directors and employees	14,890,347	2,660,159
Share-based compensation	$ 15,722,239	$ 3,286,565

INCOME TAXES (Schedule of Sourc

INCOME TAXES (Schedule of Sources and Tax Effects of Differences for Periods) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Sources and tax effects of the differences
Statutory U.S. federal tax rate	21.00%	39.00%
Effect of increase in valuation allowance	(21.00%)	(39.00%)
Effective income tax rate (as a percent)

INCOME TAXES (Schedule of Chang

INCOME TAXES (Schedule of Changes in Cumulative Net Deferred Tax Assets) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Net deferred tax assets
Net loss carry-forward	$ 11,042,420	$ 4,923,492
Valuation allowance	(11,042,420)	(4,923,492)
Net deferred tax assets

INCOME TAXES (Schedule of Recon

INCOME TAXES (Schedule of Reconciliation of Income Taxes Computed at Statutory Rate) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of income taxes computed at statutory rate
Tax benefit at statutory rate	$ 2,318,908	$ 2,023,555
Valuation allowance	(2,318,908)	(2,023,555)
Income tax expense (benefit)

SIGNIFICANT CUSTOMER INFORMAT_3

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY (Schedule of concentration of risk) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	12.00%	98.00%
Revenue [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	12.00%	2.00%
Revenue [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	8.00%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	98.00%
Accounts Receivable [Member] | Customer E [Member]
Concentration Risk [Line Items]
Concentration risk percentage	2.00%
Accounts Receivable [Member] | Customer F [Member]
Concentration Risk [Line Items]
Concentration risk percentage
Expenses [Member] | Vendor A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	7.00%	26.00%
Expenses [Member] | Vendor B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	6.00%	21.00%
Expenses [Member] | Vendor C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	5.00%	14.00%
Accounts Payable [Member] | Vendor D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	25.00%	33.00%
Accounts Payable [Member] | Vendor E [Member]
Concentration Risk [Line Items]
Concentration risk percentage	22.00%	26.00%
Accounts Payable [Member] | Vendor F [Member]
Concentration Risk [Line Items]
Concentration risk percentage	7.00%	26.00%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Aug. 03, 2018	Oct. 31, 2017
Industrial Hemp Crop Under Cultivation [Member]
Other Commitments [Line Items]
Farm lease acreage	$ 1,000
Price for harvested crop per pound	2
Accounts payable	380,000
Clinical Trial Agreement [Member] | Final Installment [Member]
Other Commitments [Line Items]
Payment made for clinical trial agreement	51,182
Prana [Member]
Other Commitments [Line Items]
Amount committed to be spent on phase I and phase 2 clinical trials during 2019 and 2020	$ 300,000
PTI [Member]
Other Commitments [Line Items]
Percentage of ownership				95.00%
Prana [Member]
Other Commitments [Line Items]
Total commitment upon execution of research agreement					$ 303,544
Commitment owed in June 2018					$ 75,886
Prana [Member] | Subsequent Event [Member]
Other Commitments [Line Items]
Total commitment upon execution of research agreement		$ 900,000	$ 700,000

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Feb. 11, 2019	Mar. 20, 2019	Jul. 18, 2017	Dec. 31, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Proceeds from notes payable				$ 1,500,000
Debt discount				$ 55,833	$ 30,453
Preferred Class A [Member] | Officer and Director [Member]
Subsequent Event [Line Items]
Number of shares issued during period			2,000
Subsequent Event [Member] | Preferred Class A [Member] | Officer and Director [Member]
Subsequent Event [Line Items]
Number of shares issued during period		1,500
Shares cancelled during period		500
Subsequent Event [Member] | Tangiers Global, LLC Note [Member]
Subsequent Event [Line Items]
Debt instrument face amount	$ 1,575,000
Proceeds from notes payable	500,000
Debt discount	$ 25,000